-
Microchip Bio's new indication for Chidamide was approved for marketing in Japan
Time of Update: 2022-02-25
In June 2021, Chidamide for monotherapy in the treatment of relapsed or refractory (R/R) adult T-cell leukemia (ATL) was approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) .
-
"Nature" solves two decades of immune mystery, prompting exposure of DNA error repair 'behind the scenes'
Time of Update: 2022-02-25
For the past two decades, the complete process by which AID works has puzzled scientists: Why doesn't DNA go the way of correct repair when the wrong base is introduced?The two research teams used genome-wide CRISPR to screen for genes involved in the B cell-induced mutation process, looking for which genes, if missing, would affect the occurrence of mutations .
-
Is the three-shot vaccine effective in neutralizing the Omicron variant?
Time of Update: 2022-02-25
However, the press release also pointed out that the Omicron variant did not affect most of the epitopes targeted by its vaccine-induced T cells, so the two companies believe that vaccinated individuals can still be protected and reduce the risk of severe COVID-19 .
-
Scientists discover novel link between CRISPR gene editing technology and mutated cancer cells
Time of Update: 2022-02-25
Recently, a research report titled "CRISPR/Cas9-induced DNA damage enriches for mutations in a p53-linked interactome: implications for CRISPR-based therapies" was published in the international journal Cancer Research, from Karolinska Institutet, Sweden, et al.
-
Study reveals spatiotemporal dynamics of human hypothalamic development
Time of Update: 2022-02-25
The hypothalamus is composed of a variety of neuronal subtypes with different shapes and functions. It is highly heterogeneous and plays an important role in the body's physiological activities and h
-
Bluebird Bio's gene therapy beti-cel receives FDA priority review
Time of Update: 2022-02-25
If approved, the therapy would be the first gene therapy in the United States to address the underlying genetic cause of the disease in patients with beta-thalassemia in a one-time treatment .
-
Nature Milestone: New Target for Non-Small Cell Lung Cancer - CLIP1-LTK
Time of Update: 2022-02-25
Transformation activity of CLIP1-LTK fusion in vivo (Source: Nature)Benefiting from the above results, the search for kinase inhibitors of CLIP1-LTK protein will have clinical therapeutic significance .
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
-
Senti Bio Announces New Advances in Next-Generation CAR-NK Therapy to Challenge AML Early data are encouraging
Time of Update: 2022-02-24
SENTI-202 combines FLT3 OR CD33 with an EMCN NOT-gated gene circuit and is designed to broadly target FLT3 and/or CD33-expressing AML tumor cells (including leukemia stem cells and immature leukemia blast subpopulations), but not healthy Hematopoietic stem cells (HSC) .
-
This type of fungal infection with a high fatality rate ushered in a new oral drug
Time of Update: 2022-02-24
According to public information, this is the first oral antifungal drug approved in mainland China for the treatment of invasive mucormycosis in adults, bringing a new treatment option for patients with this rare fungal infection with a high fatality rate .
-
Lyon Biotech's TCR-T Therapy Receives FDA Fast Track Designation for Hepatocellular Carcinoma
Time of Update: 2022-02-24
TextPharmaceutical GuanlanToday (December 23), Lion TCR Pte Ltd (Lion TCR Pte Ltd, hereinafter referred to as "Lion Bio") announced that its potential "first-in-class" therapy LioCyx-M004 has been granted Fast Track by the US FDA Eligibility for the treatment of hepatitis B-related hepatocellular carcinoma .
-
Nano "rockets" escort genetic drugs to the lesions
Time of Update: 2022-02-24
This "rocket" of only about 100 nanometers is a "polymer gene/drug carrier" constructed by Tian Huayu, a researcher at the Changchun Institute of Applied Chemistry, Chinese Academy of Sciences .
-
Ovid/AstraZeneca Collaboration to Develop Epilepsy Therapy for Novel Target
Time of Update: 2022-02-24
On January 3, 2022, Ovid Therapeutics announced that it had entered into an exclusive license agreement with AstraZeneca to acquire AstraZeneca's early development stage small molecule library targeting the KCC2 transporter, including lead candidate OV350 .
-
The "longevity medicine" that directly hits senescent cells How far are we from success?
Time of Update: 2022-02-24
The latest research progress of anti-aging cell drugsThe latest research progress of anti-aging cell drugsThe first published clinical study of Senolytic therapy was an open-label pilot trial of 14 patients with idiopathic pulmonary fibrosis (NCT02874989) who received 9 doses of dasatinib and quercetin over a 3-week period The combination (D+Q) was administered orally .
-
AstraZeneca reaches deal with Ionis to develop innovative ASO therapy over $3.5 billion
Time of Update: 2022-02-24
Eplontersen is an investigational antisense oligonucleotide (ASO) therapy developed using Ionis Ligand Conjugated Antisense (LICA) technology to treat both hereditary and non-genetic Sexual TTR amyloidosis (ATTR) .
html[3] Astrazeneca And Ionis Sign Deal To Develop And Commercialise Eplontersen.
-
This circular RNA can inhibit atherosclerosis
Time of Update: 2022-02-24
"After knocking out circEsyt2, the proliferation, migration and phenotypic transition of vascular smooth muscle cells in mice were inhibited, and at the same time, the remodeling of arterial blood vessels in mice was significantly reduced ," said Wu Gengze .
-
EMA grants Jet Behring etranacogene dezaparvovec accelerated assessment status
Time of Update: 2022-02-24
The study met its primary endpoint: Annualized Bleeding Rate (ABR) assessed after achieving steady-state factor IX (FIX) expression after a single dose, ABR at month 18 compared to baseline FIX prophylaxis showed non-inferiority (1.
The study also met the secondary endpoint of showing statistical superiority in reducing annual bleeding rates compared with baseline FIX prophylaxis (p=0.
-
The counterattack of exosomes from "cell garbage" to "seed rookie"
Time of Update: 2022-02-24
In October 2021, it also reached a cooperation agreement with MDimune to jointly develop mRNA therapy based on exosome delivery of cancer vaccines .
-
High-tech sleeping bags can effectively solve astronauts' vision problems
Time of Update: 2022-02-24
New research from the University of Texas Southwestern Medical Center suggests that a high-tech sleeping bag that draws these fluids down the lower body, reducing pressure on the brain, may offer a solution to the vision problems astronauts face .
-
Develop tumor microenvironment to activate innovative immunotherapies and explore new strategies for solid tumor treatment
Time of Update: 2022-02-24
References:[1] Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics.
Retrieved January 3, 2021, from https:// Biosciences-Secures-12-Million-Series-A-Financing-to-Advance-Immuno-Oncology-Pipeline-of-Tumor-Microenvironment-Activated-Therapeutics(Original abridged)
-
There are three basic principles for validating brain nerve cell regeneration therapy
Time of Update: 2022-02-24
Science and Technology Daily (Fu Xuan reporter Wang Chun) Recently, Peng Bo's research group of the Institute of Brain Science Translation of Fudan University, Mao Ying's research group of Huashan Hospital Affiliated to Fudan University, and Yuan Tifei's research group of Shanghai Mental Health Center used live cell imaging, rigorous NeuroD1-mediated microglia-neuron reprogramming has been systematically explored by lineage tracing and pharmacology .
